You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Managing Hypereosinophilia: Practice Your Skills

  • Authors: Michael E. Wechsler, MD
  • CME / ABIM MOC Released: 5/25/2021
  • Valid for credit through: 5/25/2022, 11:59 PM EST
Start Activity

Target Audience and Goal Statement

This activity is intended for allergists, clinical immunologists, pulmonologists, and cardiologists.

The goal of this activity is to provide guided case studies with expert feedback to allow clinicians to improve their skills in assessing and treating patients with hypereosinophilic syndrome (HES).

Upon completion of this activity, participants will:

  • Have greater competence related to
    • Diagnosing subtypes of HES
    • Applying evidence-based treatments for patients with HES
  • Demonstrate greater confidence in their ability to
    • Improve outcomes in patients with HES


As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


  • Michael E. Wechsler, MD

    Professor of Medicine
    Division of Pulmonary, Critical Care, and Sleep Medicine
    Cohen Family Asthma Institute at National Jewish Health
    National Jewish Health
    Denver, Colorado


    Disclosure: Michael E. Wechsler, MD, has the following relevant financial relationships:
    Advisor or consultant for: AstraZeneca; Cohero; Cytoreason; Genentech; Genzyme; GlaxoSmithKline; Kinaset; Novartis; Regeneron; Sanofi; Sentien
    Speaker or a member of a speakers bureau for: AstraZeneca; GlaxoSmithKline; Regeneron; Sanofi


  • Karen Badal, MD, MPH

    Senior Medical Education Director, Medscape, LLC


    Disclosure: Karen Badal, MD, MPH, has disclosed the following relevant financial relationships:
    Owns stock, stock options or bonds from: Kallyope, Inc

  • Frances McFarland, PhD, MA

    Medical Writer, Medscape, LLC


    Disclosure: Frances McFarland, PhD, MA, has disclosed no relevant financial relationships.

CME Reviewer

  • Hazel Dennison, DNP, RN, FNP-BC, CHCP, CPHQ, CNE

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Disclosure: Hazel Dennison, DNP, RN, FNP, CPHQ, CNE, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements


Interprofessional Continuing Education

In support of improving patient care, Medscape LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Managing Hypereosinophilia: Practice Your Skills

Authors: Michael E. Wechsler, MDFaculty and Disclosures

CME / ABIM MOC Released: 5/25/2021

Valid for credit through: 5/25/2022, 11:59 PM EST


The following cases are modeled on the interactive grand rounds approach. The questions within the activity are designed to test your current knowledge. After each question, you will be able to see whether you answered correctly and read evidence-based information that supports the most appropriate answer choice. The questions are designed to challenge you; you will not be penalized for answering the questions incorrectly. At the end of the activity, there will be a short post-test assessment based on the material presented.


James is a 35-year-old engineer. Four years ago, he developed a rash that did not respond to topical steroids or oral antihistamines. Three years ago, he was diagnosed with asthma, which he manages with daily inhaled corticosteroids (ICS). He has been experiencing worsening pruritic skin lesions on his extremities, torso, and back of the neck for the past 3 months, which his primary care physician has said is probably eczema. He has also been experiencing increasing dyspnea upon exertion over the past month. He has a history of anxiety.

James presents to the emergency department with shortness of breath, wheezing, and worsening pruritic skin lesions. He has no fever, but he's slightly tachycardic and tachypneic, and his blood pressure is 145/86 mm Hg. He says he is tired all the time and complains about the stress of the pandemic and the effects it has had on the company where he works; he adds that his worsening rash and fatigue do not help matters. When asked about his current medications, James reports that he is taking daily ICS for asthma, along with daily oral corticosteroids for the rash and anti-anxiety medication. James also notes that he has tried to stop the oral corticosteroids because he does not like the way they make him feel. He has been experiencing mood swings and thinning hair, and he has been gaining weight. However, when he has tried to stop the corticosteroids, his rash worsens. His previous laboratory measures, which are in the system, show that he had an elevated eosinophil count, 11% of his white blood cell count, 3 years ago.

  • Print